1. Embelin: a benzoquinone possesses therapeutic potential for the treatment of human cancer
- Author
-
Kirti S. Prabhu, Abdul Quaiyoom Khan, Shilpa Kuttikrishnan, Iman W. Achkar, Kodapully S Siveen, Shahab Uddin, and Sabah Akhtar
- Subjects
0301 basic medicine ,Embelia ribes ,Embelia ,Apoptosis ,03 medical and health sciences ,0302 clinical medicine ,Neoplasms ,Drug Discovery ,Benzoquinones ,medicine ,Animals ,Humans ,Protein kinase B ,Cell Proliferation ,Pharmacology ,biology ,Cell growth ,Cancer ,JAK-STAT signaling pathway ,medicine.disease ,biology.organism_classification ,Antineoplastic Agents, Phytogenic ,XIAP ,030104 developmental biology ,Drug development ,030220 oncology & carcinogenesis ,Cancer cell ,Cancer research ,Molecular Medicine ,Signal Transduction - Abstract
Natural products have been gaining recognition and are becoming a significant part of research in the area of drug development and discovery. Phytochemicals derived from these sources have been comprehensively studied and have displayed a wide range of activities against many fatal diseases including cancer. One such product that has gained recognition from its pharmacological properties and nontoxic nature is embelin, obtained from Embelia ribes. Amid all the vivid pharmacological activities, embelin has gained its prominence in the area of cancer research. Embelin binds to the BIR3 domain of XIAP, preventing the association of XIAP and caspase-9 resulting in the suppression of cell growth, proliferation and migration of various types of cancer cells. Furthermore, embelin modulates anti-apoptotic pathways by suppressing the activity of NF-κB, PI3-kinase/AKT, JAK/STAT pathway – among others. The present review summarizes the various reported effects of embelin on different types of cancer cells and highlights the cellular mechanisms of action.
- Published
- 2018
- Full Text
- View/download PDF